John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive

MENU

Interest of therapeutic sequencing in the management of IBD Volume 28, supplement 5, November 2021

Figures

  • Figure 1
  • Figure 2
  • Figure 3
  • Figure 4
  • Figure 5
  • Figure 6
  • Figure 7

Tables

Author
CHU de Saint-Étienne, Service d’hépato-gastro-entérologie, Avenue Albert Raimond, 42270 Saint-Priest-en-Jarez
* Correspondance

Inflammatory Bowel Disease (IBD) treatment is now improved with news molecules associated with a more important armamentarium to treat our patients. However, if these drugs were associated significantly with clinical response or remission, these rates are actually stable in comparison with other drugs. Moreover, in IBD patients treated before with anti-TNF drugs, all treatments were negatively impacted with this first line. So, in the future, we must choose the first line according to patient and activity of disease but also with the idea to positively impact response to a second line. It is the theory of sequencing.